Literature DB >> 18854576

Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation.

Michael Heuser1, Damian B Yap, Malina Leung, Teresa Ruiz de Algara, Alaeddin Tafech, Steven McKinney, John Dixon, Rosemary Thresher, Bill Colledge, Mark Carlton, R Keith Humphries, Samuel A Aparicio.   

Abstract

MLL5 is a divergent member of the Drosophila Trithorax-related (SET) domain and plant homeodomain (PHD) domain-containing chromatin regulators that are involved in the regulation of transcriptional "memory" during differentiation. Human MLL5 is located on chromosome 7q22, which frequently is deleted in myeloid leukemias, suggesting a possible role in hemopoiesis. To address this question, we generated a loss-of-function allele (Mll5(tm1Apa)) in the murine Mll5 locus. Unlike other Mll genes, Mll5(tm1Apa) homozygous mice are viable but display defects in immunity and hematopoiesis. First, Mll5(tm1Apa) homozygous mice show increased susceptibility to spontaneous eye infections, associated with a cell-autonomous impairment of neutrophil function. Second, Mll5(tm1Apa/tm1Apa) mice exhibit a mild impairment of erythropoiesis. Third, Mll5(tm1Apa/tm1Apa) hematopoietic stem cells (HSCs) have impaired competitive repopulating capacity both under normal conditions and when subjected to self-renewal stimulation by NUP98-HOXA10. Fourth, Mll5(tm1Apa) homozygous HSCs show a dramatic sensitivity to DNA demethylation-induced differentiation (5-azadeoxycytidine). Taken together, our data show that MLL5 is involved in terminal myeloid differentiation and the regulation of HSC self-renewal by a mechanism that involves DNA methylation. These data warrant investigation of MLL5 expression levels as a predictive marker of demethylating-agent response in patients with myelodysplastic syndromes and leukemias and identify MLL5 as a key regulator of normal hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18854576     DOI: 10.1182/blood-2008-06-162263

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  55 in total

Review 1.  Epigenetics in myelodysplastic syndromes.

Authors:  Michael Heuser; Haiyang Yun; Felicitas Thol
Journal:  Semin Cancer Biol       Date:  2017-08-02       Impact factor: 15.707

Review 2.  Trithorax group proteins: switching genes on and keeping them active.

Authors:  Bernd Schuettengruber; Anne-Marie Martinez; Nicola Iovino; Giacomo Cavalli
Journal:  Nat Rev Mol Cell Biol       Date:  2011-11-23       Impact factor: 94.444

3.  Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling.

Authors:  A Sharma; H Yun; N Jyotsana; A Chaturvedi; A Schwarzer; E Yung; C K Lai; F Kuchenbauer; B Argiropoulos; K Görlich; A Ganser; R K Humphries; M Heuser
Journal:  Leukemia       Date:  2014-05-20       Impact factor: 11.528

4.  Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms.

Authors:  Rashmi S Goswami; Sa A Wang; Courtney DiNardo; Zhenya Tang; Yan Li; Wenli Zuo; Shimin Hu; Shaoying Li; L Jeffrey Medeiros; Guilin Tang
Journal:  Mod Pathol       Date:  2016-04-08       Impact factor: 7.842

5.  KMT2E-ASNS: a novel relapse-specific fusion gene in early T-cell precursor acute lymphoblastic leukemia.

Authors:  Fida Khater; Mathieu Lajoie; Sylvie Langlois; Jasmine Healy; Sonia Cellot; Chantal Richer; Patrick Beaulieu; Pascal St-Onge; Virginie Saillour; Mark Minden; Monia Marzouki; Maja Krajinovic; Henrique Bittencourt; Daniel Sinnett
Journal:  Blood       Date:  2017-01-09       Impact factor: 22.113

Review 6.  MLL5 (KMT2E): structure, function, and clinical relevance.

Authors:  Xiaoming Zhang; Wisna Novera; Yan Zhang; Lih-Wen Deng
Journal:  Cell Mol Life Sci       Date:  2017-02-10       Impact factor: 9.261

Review 7.  Histone-modifying enzymes: regulators of developmental decisions and drivers of human disease.

Authors:  Jill S Butler; Evangelia Koutelou; Andria C Schibler; Sharon Y R Dent
Journal:  Epigenomics       Date:  2012-04       Impact factor: 4.778

Review 8.  Chromatin regulatory mechanisms in pluripotency.

Authors:  Julie A Lessard; Gerald R Crabtree
Journal:  Annu Rev Cell Dev Biol       Date:  2010       Impact factor: 13.827

Review 9.  Molecular pathophysiology of myelodysplastic syndromes.

Authors:  R Coleman Lindsley; Benjamin L Ebert
Journal:  Annu Rev Pathol       Date:  2012-08-28       Impact factor: 23.472

10.  UpSET-ting the balance: modulating open chromatin features in metazoan genomes.

Authors:  Hector Rincon-Arano; Susan M Parkhurst; Mark Groudine
Journal:  Fly (Austin)       Date:  2013-05-06       Impact factor: 2.160

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.